What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Surgery
- Cancer
Martin H. Prins mostly deals with Surgery, Internal medicine, Venous thrombosis, Thrombosis and Pulmonary embolism.
His Surgery research incorporates elements of Cancer and Risk factor.
His work in Internal medicine addresses subjects such as Cardiology, which are connected to disciplines such as Mortality rate.
His Venous thrombosis study combines topics in areas such as Fondaparinux Sodium, Complication, Incidence and Confidence interval.
The Thrombosis study which covers Vascular disease that intersects with Radiology and Angiography.
The Pulmonary embolism study combines topics in areas such as Respiratory disease, Prospective cohort study, Idraparinux and Vitamin K antagonist.
His most cited work include:
- Oral rivaroxaban for symptomatic venous thromboembolism (2257 citations)
- Low-Molecular-Weight Heparin versus a Coumarin for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (1851 citations)
- The long-term clinical course of acute deep venous thrombosis. (1741 citations)
What are the main themes of his work throughout his whole career to date?
His primary areas of investigation include Internal medicine, Surgery, Thrombosis, Pulmonary embolism and Venous thrombosis.
His biological study spans a wide range of topics, including Gastroenterology and Cardiology.
His Surgery research incorporates themes from Confidence interval, Hazard ratio and Incidence.
Martin H. Prins interconnects Anesthesia and Heparin in the investigation of issues within Thrombosis.
His studies deal with areas such as Idraparinux, Radiology and Warfarin as well as Pulmonary embolism.
The study incorporates disciplines such as Cancer, Complication and Vascular disease in addition to Venous thrombosis.
He most often published in these fields:
- Internal medicine (42.43%)
- Surgery (34.12%)
- Thrombosis (23.45%)
What were the highlights of his more recent work (between 2012-2021)?
- Internal medicine (42.43%)
- Rivaroxaban (9.59%)
- Thrombosis (23.45%)
In recent papers he was focusing on the following fields of study:
His main research concerns Internal medicine, Rivaroxaban, Thrombosis, Pulmonary embolism and Randomized controlled trial.
His work is dedicated to discovering how Internal medicine, Cardiology are connected with Peripheral and other disciplines.
His research integrates issues of Anesthesia, Surgery, Incidence, Vitamin K antagonist and Aspirin in his study of Rivaroxaban.
Martin H. Prins works in the field of Surgery, focusing on Anticoagulant in particular.
His study in Deep vein and Venous thrombosis falls within the category of Thrombosis.
His research in Pulmonary embolism intersects with topics in Stroke, Fibrinolytic agent, Idraparinux and Warfarin.
Between 2012 and 2021, his most popular works were:
- Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism (1218 citations)
- International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer (422 citations)
- Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies (383 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Surgery
- Disease
His primary areas of study are Internal medicine, Rivaroxaban, Pulmonary embolism, Thrombosis and Surgery.
As a part of the same scientific family, Martin H. Prins mostly works in the field of Internal medicine, focusing on Cardiology and, on occasion, Comorbidity, Radiology and Stroke.
His studies in Rivaroxaban integrate themes in fields like Angiology, Anesthesia and Vitamin K antagonist.
His Pulmonary embolism study integrates concerns from other disciplines, such as First episode, Fibrinolytic agent and Warfarin.
His Thrombosis research is multidisciplinary, relying on both Adverse effect and Randomized controlled trial.
Martin H. Prins studies Surgery, namely Anticoagulant.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
